CATALIO CAPITAL MANAGEMENT, LP 13F Portfolio
CATALIO CAPITAL MANAGEMENT, LP runs CATALIO CAPITAL MANAGEMENT, LP and currently holds 39 stock positions, which is fewer than the average of 231 among the investors we track. The portfolio is valued at approximately $532.10M. Their top holdings are AVLN, JNJ, GILD, BBIO, SNDX. The top five represent 34.8% of reported portfolio weight. CATALIO CAPITAL MANAGEMENT, LP ranks #547 out of 1000 investors tracked by Alpha Score. In the most recent quarter, CATALIO CAPITAL MANAGEMENT, LP initiated 8 new positions. They added to 13 existing positions. They trimmed 8 positions. Their current best-performing preview position is DFTX with returns of +148.89%.
Portfolio Value
$532.10M
Alpha Score
55.2
#547 of 1000
Holdings
39
CATALIO CAPITAL MANAGEMENT, LP Current 13F Holdings
Reported holdings from CATALIO CAPITAL MANAGEMENT, LP's latest SEC 13F filing, ranked by portfolio weight.
39 stock holdings
| Holding | Weight | Avg Buy | Current | Return | Quarter Change |
|---|---|---|---|---|---|
AV AVLN AVALYN PHARMACEUTICALS INC | 10.37% | $32.92 | $25.76 | -21.75% | New Buy |
 JNJ JOHNSON & JOHNSON | 6.63% | $253.97 | $261.49 | +2.96% | Added +100.00% |
 GILD GILEAD SCIENCES INC | 6.39% | $124.15 | $151.17 | +21.76% | Added +64.31% |
 BBIO BRIDGEBIO PHARMA INC | 6.37% | $74.27 | $65.35 | -12.01% | Added +5.33% |
 SNDX SYNDAX PHARMACEUTICALS INC | 4.99% | $13.20 | $16.99 | +28.71% | Added +16.48% |
 DFTX DEFINIUM THERAPEUTICS INC | 4.97% | $18.90 | $36.90 | +95.24% | Trimmed -45.79% |
 BMY BRISTOL-MYERS SQUIBB CO | 4.47% | $53.94 | $59.11 | +9.58% | Trimmed -1.85% |
AA AADX PARABILIS MEDICINES INC | 4.24% | $22.78 | $11.46 | -49.69% | New Buy |
 NTRA NATERA INC | 4.19% | $184.19 | $400.71 | +117.55% | Added +15.90% |
 INCY INCYTE CORP | 4.08% | $95.08 | $112.79 | +18.63% | Added +5.23% |
Showing 1-10 of 39